VIR•benzinga•May 9, 2025 at 10:10 AM

Vir Biotechnology Reveals Preliminary 24-Week Post-End of Treatment Data For Tobevibart And Elebsiran Combinations In Chronic Hepatitis B From MARCH Study, Reiterates Cash Runway Guidance Into Mid-2027, Based On The Current Operating Plan

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 9, 2025 by benzinga